SK pharmteco has announced the successful completion of a regulatory inspection conducted by the U.S. Food and Drug Administration (FDA) at its small molecule facility in La Porte, Texas. The inspection results confirm that the site adheres to the highest standards of operational excellence and quality systems.
Comprehensive evaluation and optimal outcome Following a thorough review, the FDA concluded the inspection with a “No Action Indicated” (NAI) status and did not issue a Form 483. This status serves as a top-tier certification that the facility remains in full compliance with current regulatory mandates.
The general inspection encompassed both physical tours and in-depth procedural audits:
-
Infrastructure Survey: Inspectors toured the warehouse, the manufacturing plant, and analytical laboratories.
-
Procedural Verification: The agency conducted a detailed review of batch records, Corrective and Preventive Actions (CAPAs), deviation and Out-of-Specification (OOS) investigations, and change controls.
-
Technical Integrity: The FDA also confirmed the validity of equipment qualifications, purified water systems, and both process and cleaning validations.
Commitment to quality and supply reliability Leadership from SK pharmteco’s North American small molecule division emphasized that maintaining NAI status is a significant milestone, reflecting the disciplined quality culture of the La Porte team.
This outcome not only strengthens the credibility of their management systems but also reassures customers of the company’s capability for secure, compliant, and uninterrupted manufacturing of essential medicines. Clearing the inspection without findings further solidifies SK pharmteco’s position within the global pharmaceutical supply chain in North America.